Review



fcs express 7 flow cytometry ruo  (GraphPad Software Inc)


Bioz Verified Symbol GraphPad Software Inc is a verified supplier  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    GraphPad Software Inc fcs express 7 flow cytometry ruo
    a The murine T-lymphoma cell line, EL4-hCD20, highly expresses H-2K b versus the normal T cells of wild-type C57BL/6 mice. H-2K b is the MHC class I molecule for C57BL/6 mice. b Two independent sets of experiments, one based on flow <t>cytometry</t> and one based on LDH release detection, indicated increased ADCC against murine T-lymphoma cells during Ly49 C/I blockade. Ly49 C and Ly49 I are specific inhibitory receptors on NK cells in mice ( N = 6). Data were presented as mean values +/– SEM. The p values were calculated using paired, two-tailed student’s t test. c Schematic representation of the in vivo mouse experiment. C57BL/6 mice were inoculated subcutaneously with 1 × 10 5 EL4-hCD20 T-lymphoma cells. After tumor inoculation, mice received 250 µg of therapeutic anti-hCD20-mIgG2a or isotype IgG2a control on day 3 and once weekly for three weeks, 200 µg of blocking anti-Ly49 C/I F(ab’) 2 or isotype IgG2a F(ab’) 2 on day 3 and biweekly for three weeks, or a combination of anti-hCD20-mIgG2a and anti‑Ly49 C/I F(ab’) 2 . Therapeutic and blocking antibodies were administered i.p. The schematic representation is created with BioRender.com. d Tumor tracking and intensity of luminescence signals from tumor cells as measured by IVIS ( N = 10). On day 3 before treatment, the mice were confirmed to have successful EL4-hCD20 tumor inoculation, and the intensity of luminescence signals was approximately equal in each group. On day 9 after treatment, tumor cells remained only in the skin and no metastasis had occurred. In addition, the intensity of luminescence signals indicated that Ly49 blockade enhances the anti-T–cell lymphoma activity of anti-hCD20 therapeutic antibody. Data were presented as mean values +/– SEM. e The tumor growth curve illustrated that both anti-hCD20 therapeutic antibody and Ly49 C/I F(ab’) 2 blocking antibody were able to inhibit tumor growth in the skin, and the combination of both antibodies significantly inhibited tumor growth in the skin ( N = 10). Data were presented as mean values +/– SEM. The p values were calculated using unpaired, two-tailed student’s t test from the data on day 13. n.s., not significant. f The combination of anti-hCD20 therapeutic antibody and Ly49 C/I F(ab’) 2 blocking antibody against T-cell lymphoma in the skin significantly increased overall survival ( N = 10). The p values were calculated using simple survival analysis (Kaplan-Meier). n.s., not significant. Source data are provided as a Source Data file.
    Fcs Express 7 Flow Cytometry Ruo, supplied by GraphPad Software Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/fcs express 7 flow cytometry ruo/product/GraphPad Software Inc
    Average 90 stars, based on 1 article reviews
    fcs express 7 flow cytometry ruo - by Bioz Stars, 2026-05
    90/100 stars

    Images

    1) Product Images from "MHC-I upregulation safeguards neoplastic T cells in the skin against NK cell-mediated eradication in mycosis fungoides"

    Article Title: MHC-I upregulation safeguards neoplastic T cells in the skin against NK cell-mediated eradication in mycosis fungoides

    Journal: Nature Communications

    doi: 10.1038/s41467-024-45083-8

    a The murine T-lymphoma cell line, EL4-hCD20, highly expresses H-2K b versus the normal T cells of wild-type C57BL/6 mice. H-2K b is the MHC class I molecule for C57BL/6 mice. b Two independent sets of experiments, one based on flow cytometry and one based on LDH release detection, indicated increased ADCC against murine T-lymphoma cells during Ly49 C/I blockade. Ly49 C and Ly49 I are specific inhibitory receptors on NK cells in mice ( N = 6). Data were presented as mean values +/– SEM. The p values were calculated using paired, two-tailed student’s t test. c Schematic representation of the in vivo mouse experiment. C57BL/6 mice were inoculated subcutaneously with 1 × 10 5 EL4-hCD20 T-lymphoma cells. After tumor inoculation, mice received 250 µg of therapeutic anti-hCD20-mIgG2a or isotype IgG2a control on day 3 and once weekly for three weeks, 200 µg of blocking anti-Ly49 C/I F(ab’) 2 or isotype IgG2a F(ab’) 2 on day 3 and biweekly for three weeks, or a combination of anti-hCD20-mIgG2a and anti‑Ly49 C/I F(ab’) 2 . Therapeutic and blocking antibodies were administered i.p. The schematic representation is created with BioRender.com. d Tumor tracking and intensity of luminescence signals from tumor cells as measured by IVIS ( N = 10). On day 3 before treatment, the mice were confirmed to have successful EL4-hCD20 tumor inoculation, and the intensity of luminescence signals was approximately equal in each group. On day 9 after treatment, tumor cells remained only in the skin and no metastasis had occurred. In addition, the intensity of luminescence signals indicated that Ly49 blockade enhances the anti-T–cell lymphoma activity of anti-hCD20 therapeutic antibody. Data were presented as mean values +/– SEM. e The tumor growth curve illustrated that both anti-hCD20 therapeutic antibody and Ly49 C/I F(ab’) 2 blocking antibody were able to inhibit tumor growth in the skin, and the combination of both antibodies significantly inhibited tumor growth in the skin ( N = 10). Data were presented as mean values +/– SEM. The p values were calculated using unpaired, two-tailed student’s t test from the data on day 13. n.s., not significant. f The combination of anti-hCD20 therapeutic antibody and Ly49 C/I F(ab’) 2 blocking antibody against T-cell lymphoma in the skin significantly increased overall survival ( N = 10). The p values were calculated using simple survival analysis (Kaplan-Meier). n.s., not significant. Source data are provided as a Source Data file.
    Figure Legend Snippet: a The murine T-lymphoma cell line, EL4-hCD20, highly expresses H-2K b versus the normal T cells of wild-type C57BL/6 mice. H-2K b is the MHC class I molecule for C57BL/6 mice. b Two independent sets of experiments, one based on flow cytometry and one based on LDH release detection, indicated increased ADCC against murine T-lymphoma cells during Ly49 C/I blockade. Ly49 C and Ly49 I are specific inhibitory receptors on NK cells in mice ( N = 6). Data were presented as mean values +/– SEM. The p values were calculated using paired, two-tailed student’s t test. c Schematic representation of the in vivo mouse experiment. C57BL/6 mice were inoculated subcutaneously with 1 × 10 5 EL4-hCD20 T-lymphoma cells. After tumor inoculation, mice received 250 µg of therapeutic anti-hCD20-mIgG2a or isotype IgG2a control on day 3 and once weekly for three weeks, 200 µg of blocking anti-Ly49 C/I F(ab’) 2 or isotype IgG2a F(ab’) 2 on day 3 and biweekly for three weeks, or a combination of anti-hCD20-mIgG2a and anti‑Ly49 C/I F(ab’) 2 . Therapeutic and blocking antibodies were administered i.p. The schematic representation is created with BioRender.com. d Tumor tracking and intensity of luminescence signals from tumor cells as measured by IVIS ( N = 10). On day 3 before treatment, the mice were confirmed to have successful EL4-hCD20 tumor inoculation, and the intensity of luminescence signals was approximately equal in each group. On day 9 after treatment, tumor cells remained only in the skin and no metastasis had occurred. In addition, the intensity of luminescence signals indicated that Ly49 blockade enhances the anti-T–cell lymphoma activity of anti-hCD20 therapeutic antibody. Data were presented as mean values +/– SEM. e The tumor growth curve illustrated that both anti-hCD20 therapeutic antibody and Ly49 C/I F(ab’) 2 blocking antibody were able to inhibit tumor growth in the skin, and the combination of both antibodies significantly inhibited tumor growth in the skin ( N = 10). Data were presented as mean values +/– SEM. The p values were calculated using unpaired, two-tailed student’s t test from the data on day 13. n.s., not significant. f The combination of anti-hCD20 therapeutic antibody and Ly49 C/I F(ab’) 2 blocking antibody against T-cell lymphoma in the skin significantly increased overall survival ( N = 10). The p values were calculated using simple survival analysis (Kaplan-Meier). n.s., not significant. Source data are provided as a Source Data file.

    Techniques Used: Flow Cytometry, Two Tailed Test, In Vivo, Control, Blocking Assay, Activity Assay



    Similar Products

    fcs express 7 flow cytometry ruo  (GraphPad Software Inc)
    90
    GraphPad Software Inc fcs express 7 flow cytometry ruo
    a The murine T-lymphoma cell line, EL4-hCD20, highly expresses H-2K b versus the normal T cells of wild-type C57BL/6 mice. H-2K b is the MHC class I molecule for C57BL/6 mice. b Two independent sets of experiments, one based on flow <t>cytometry</t> and one based on LDH release detection, indicated increased ADCC against murine T-lymphoma cells during Ly49 C/I blockade. Ly49 C and Ly49 I are specific inhibitory receptors on NK cells in mice ( N = 6). Data were presented as mean values +/– SEM. The p values were calculated using paired, two-tailed student’s t test. c Schematic representation of the in vivo mouse experiment. C57BL/6 mice were inoculated subcutaneously with 1 × 10 5 EL4-hCD20 T-lymphoma cells. After tumor inoculation, mice received 250 µg of therapeutic anti-hCD20-mIgG2a or isotype IgG2a control on day 3 and once weekly for three weeks, 200 µg of blocking anti-Ly49 C/I F(ab’) 2 or isotype IgG2a F(ab’) 2 on day 3 and biweekly for three weeks, or a combination of anti-hCD20-mIgG2a and anti‑Ly49 C/I F(ab’) 2 . Therapeutic and blocking antibodies were administered i.p. The schematic representation is created with BioRender.com. d Tumor tracking and intensity of luminescence signals from tumor cells as measured by IVIS ( N = 10). On day 3 before treatment, the mice were confirmed to have successful EL4-hCD20 tumor inoculation, and the intensity of luminescence signals was approximately equal in each group. On day 9 after treatment, tumor cells remained only in the skin and no metastasis had occurred. In addition, the intensity of luminescence signals indicated that Ly49 blockade enhances the anti-T–cell lymphoma activity of anti-hCD20 therapeutic antibody. Data were presented as mean values +/– SEM. e The tumor growth curve illustrated that both anti-hCD20 therapeutic antibody and Ly49 C/I F(ab’) 2 blocking antibody were able to inhibit tumor growth in the skin, and the combination of both antibodies significantly inhibited tumor growth in the skin ( N = 10). Data were presented as mean values +/– SEM. The p values were calculated using unpaired, two-tailed student’s t test from the data on day 13. n.s., not significant. f The combination of anti-hCD20 therapeutic antibody and Ly49 C/I F(ab’) 2 blocking antibody against T-cell lymphoma in the skin significantly increased overall survival ( N = 10). The p values were calculated using simple survival analysis (Kaplan-Meier). n.s., not significant. Source data are provided as a Source Data file.
    Fcs Express 7 Flow Cytometry Ruo, supplied by GraphPad Software Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/fcs express 7 flow cytometry ruo/product/GraphPad Software Inc
    Average 90 stars, based on 1 article reviews
    fcs express 7 flow cytometry ruo - by Bioz Stars, 2026-05
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    a The murine T-lymphoma cell line, EL4-hCD20, highly expresses H-2K b versus the normal T cells of wild-type C57BL/6 mice. H-2K b is the MHC class I molecule for C57BL/6 mice. b Two independent sets of experiments, one based on flow cytometry and one based on LDH release detection, indicated increased ADCC against murine T-lymphoma cells during Ly49 C/I blockade. Ly49 C and Ly49 I are specific inhibitory receptors on NK cells in mice ( N = 6). Data were presented as mean values +/– SEM. The p values were calculated using paired, two-tailed student’s t test. c Schematic representation of the in vivo mouse experiment. C57BL/6 mice were inoculated subcutaneously with 1 × 10 5 EL4-hCD20 T-lymphoma cells. After tumor inoculation, mice received 250 µg of therapeutic anti-hCD20-mIgG2a or isotype IgG2a control on day 3 and once weekly for three weeks, 200 µg of blocking anti-Ly49 C/I F(ab’) 2 or isotype IgG2a F(ab’) 2 on day 3 and biweekly for three weeks, or a combination of anti-hCD20-mIgG2a and anti‑Ly49 C/I F(ab’) 2 . Therapeutic and blocking antibodies were administered i.p. The schematic representation is created with BioRender.com. d Tumor tracking and intensity of luminescence signals from tumor cells as measured by IVIS ( N = 10). On day 3 before treatment, the mice were confirmed to have successful EL4-hCD20 tumor inoculation, and the intensity of luminescence signals was approximately equal in each group. On day 9 after treatment, tumor cells remained only in the skin and no metastasis had occurred. In addition, the intensity of luminescence signals indicated that Ly49 blockade enhances the anti-T–cell lymphoma activity of anti-hCD20 therapeutic antibody. Data were presented as mean values +/– SEM. e The tumor growth curve illustrated that both anti-hCD20 therapeutic antibody and Ly49 C/I F(ab’) 2 blocking antibody were able to inhibit tumor growth in the skin, and the combination of both antibodies significantly inhibited tumor growth in the skin ( N = 10). Data were presented as mean values +/– SEM. The p values were calculated using unpaired, two-tailed student’s t test from the data on day 13. n.s., not significant. f The combination of anti-hCD20 therapeutic antibody and Ly49 C/I F(ab’) 2 blocking antibody against T-cell lymphoma in the skin significantly increased overall survival ( N = 10). The p values were calculated using simple survival analysis (Kaplan-Meier). n.s., not significant. Source data are provided as a Source Data file.

    Journal: Nature Communications

    Article Title: MHC-I upregulation safeguards neoplastic T cells in the skin against NK cell-mediated eradication in mycosis fungoides

    doi: 10.1038/s41467-024-45083-8

    Figure Lengend Snippet: a The murine T-lymphoma cell line, EL4-hCD20, highly expresses H-2K b versus the normal T cells of wild-type C57BL/6 mice. H-2K b is the MHC class I molecule for C57BL/6 mice. b Two independent sets of experiments, one based on flow cytometry and one based on LDH release detection, indicated increased ADCC against murine T-lymphoma cells during Ly49 C/I blockade. Ly49 C and Ly49 I are specific inhibitory receptors on NK cells in mice ( N = 6). Data were presented as mean values +/– SEM. The p values were calculated using paired, two-tailed student’s t test. c Schematic representation of the in vivo mouse experiment. C57BL/6 mice were inoculated subcutaneously with 1 × 10 5 EL4-hCD20 T-lymphoma cells. After tumor inoculation, mice received 250 µg of therapeutic anti-hCD20-mIgG2a or isotype IgG2a control on day 3 and once weekly for three weeks, 200 µg of blocking anti-Ly49 C/I F(ab’) 2 or isotype IgG2a F(ab’) 2 on day 3 and biweekly for three weeks, or a combination of anti-hCD20-mIgG2a and anti‑Ly49 C/I F(ab’) 2 . Therapeutic and blocking antibodies were administered i.p. The schematic representation is created with BioRender.com. d Tumor tracking and intensity of luminescence signals from tumor cells as measured by IVIS ( N = 10). On day 3 before treatment, the mice were confirmed to have successful EL4-hCD20 tumor inoculation, and the intensity of luminescence signals was approximately equal in each group. On day 9 after treatment, tumor cells remained only in the skin and no metastasis had occurred. In addition, the intensity of luminescence signals indicated that Ly49 blockade enhances the anti-T–cell lymphoma activity of anti-hCD20 therapeutic antibody. Data were presented as mean values +/– SEM. e The tumor growth curve illustrated that both anti-hCD20 therapeutic antibody and Ly49 C/I F(ab’) 2 blocking antibody were able to inhibit tumor growth in the skin, and the combination of both antibodies significantly inhibited tumor growth in the skin ( N = 10). Data were presented as mean values +/– SEM. The p values were calculated using unpaired, two-tailed student’s t test from the data on day 13. n.s., not significant. f The combination of anti-hCD20 therapeutic antibody and Ly49 C/I F(ab’) 2 blocking antibody against T-cell lymphoma in the skin significantly increased overall survival ( N = 10). The p values were calculated using simple survival analysis (Kaplan-Meier). n.s., not significant. Source data are provided as a Source Data file.

    Article Snippet: Data were analyzed using FCS Express 7 Flow Cytometry RUO and Prism V9.1.0 (GraphPad) software.

    Techniques: Flow Cytometry, Two Tailed Test, In Vivo, Control, Blocking Assay, Activity Assay